Tretinoin, azacitidine, and venetoclax for untreated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have a new diagnosis of AML (not a type called APL).
- You must not have received prior chemotherapy for AML (except hydroxyurea or a procedure to lower white blood cells).
- Your white blood cell count must be 25,000 or lower.
- You must be well enough to perform daily activities (ECOG score 0–2).
- Your kidney and liver function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of venetoclax and azacitidine for people with newly diagnosed acute myeloid leukemia (AML) who cannot have or choose not to have intensive chemotherapy. The goal is to see if adding a drug called cobicistat helps the treatment work better.
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.